Cabergoline for bodybuilder's is pretty safe (study)

[Swifto]

Large doses of Cebergoline have been linked to serious heart valvue damage. Perticularly in perkinson's patients who take around 2-5mg/ED.

In our doses it was postulated that there may also be some harm.

Below is a study on low doses for treating hyperprolactinaemia for a period of 3–4 years and they concluded it is infact safe.



Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Ammar Wakil, Alan S Rigby1, Andrew L Clark2, Anna Kallvikbacka-Bennett2 and Stephen L Atkin3

Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK1 Department of Academic Cardiology, University of Hull, Hull, UK2 Castle Hill Hospital, Castle Road, Cottingham, UK3 Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK

(Correspondence should be addressed to A Wakil; Email: [email protected])

Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.

Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.

Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).

Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.

I know some use Caber and other D2 agonist's to treat increased PRL. So this is relevant to those user's. I dont see a need to run a D2 agonist as a preventtive measure when using 19-Nor's as an AI is fiarly effective.

[VR4]

Great post swifto...good to know. Thanks.
I just started my caber for my tren 3 days ago...so far so good

[Swifto]

Great post swifto...good to know. Thanks.
I just started my caber for my tren 3 days ago...so far so good

It was about 3 years back I was the first to post a study linking Cabergolone and heart valvue damage. Now this study has confirmed its actually safe.

Even I am wrong now and again...

My opinoins change witht he times.

I remember when HCG used for PCT made people fall of their chair and combining it with Clomid was suicide! Tamoxifen to counter estrogenic sides, that sorta thing.

[marcus300]

Nice post

[Swifto]

Anyone rants and raves about Cabergoline point them over here.

[PK-V]

Great post swifto...good to know. Thanks.
I just started my caber for my tren 3 days ago...so far so good

this

Anyone rants and raves about Cabergoline point them over here.

with pleasure

[ProEvoDanny]

....

[songdog]

good post

[tboney]

Large doses of Cebergoline have been linked to serious heart valvue damage. Perticularly in perkinson's patients who take around 2-5mg/ED.

In our doses it was postulated that there may also be some harm.

Below is a study on low doses for treating hyperprolactinaemia for a period of 3–4 years and they concluded it is infact safe.



Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease

Ammar Wakil, Alan S Rigby1, Andrew L Clark2, Anna Kallvikbacka-Bennett2 and Stephen L Atkin3

Michael White Diabetes Centre, Hull Royal Infirmary, Brocklehurst Building, 220-236 Anlaby Road, Hull HU3 2RW, UK1 Department of Academic Cardiology, University of Hull, Hull, UK2 Castle Hill Hospital, Castle Road, Cottingham, UK3 Department of Endocrinology, Diabetes and Metabolism, Hull York Medical School, Hull, UK

(Correspondence should be addressed to A Wakil; Email: [email protected])

Objective: Recent trials suggest that using ergot-derived dopamine agonists such as cabergoline in the treatment of Parkinson's disease is associated with an increased risk of valvular heart disease. However, the dose of cabergoline used to treat hyperprolactinaemia is considerably less than that used in Parkinson's disease.

Design and methods: A cross-sectional comparative assessment. Forty-four patients treated with cabergoline for hyperprolactinaemia underwent transthoracic echocardiography and were compared with 566 sequential subjects complaining of palpitations, taken from a contemporary echocardiography database.

Results: The mean cumulative dose of cabergoline in the cases was 311 mg. There was no significant, severe or moderate, right- or left-sided valvular regurgitation in either group. Left heart: in the mitral and aortic valves, the rate of mild and trivial valvular regurgitation was not different between the two groups. Right heart: mild tricuspid and pulmonary regurgitation on colour Doppler alone was increased significantly in the cabergoline group, odds ratios of 3.1 and 7.8 respectively (95% confidence interval 1.0–9.6 and 0.8–78.4, P=0.04 and P<0.0001 respectively).

Conclusion: Cabergoline at doses sufficient to suppress hyperprolactinaemia for a period of 3–4 years is not associated with an increased risk of clinically significant valvular regurgitation.

I know some use Caber and other D2 agonist's to treat increased PRL. So this is relevant to those user's. I dont see a need to run a D2 agonist as a preventtive measure when using 19-Nor's as an AI is fiarly effective.

Quite often I hear people talking about using caber for the sexual sides that it produces.... Is it safe to say that we can use it at the recommended doses for a period of 4 to 6 weeks(during pct), even if we are not suffering from hyperprolatinaemia????

[Swifto]

I'd say so, yes.

[Bossman]

Thanks for the info Swifto!

[charliemurphy229]

very good caber info.....